Renal protective effect of YM598, a selective endothelin ETA receptor antagonist, against diabetic nephropathy in OLETF rats

European Journal of Pharmacology

Volumn 450, Issue 2, 2002, Pages 183-189

  Sugimoto, Koh ichi ^a   Tsuruoka, Shuichi ^a   Fujimura, Akio ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Diabetic nephropathy; Diabetic, rat; Endothelin; Endothelin ETA receptor antagonist

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; POTASSIUM N [6 METHOXY 5 (2 METHOXYPHENOXY) 2 (PYRIMIDIN 2 YL)PYRIMIDIN 4 YL] 2 PHENYLENTHENESULFONAMIDATE; UNCLASSIFIED DRUG; YM 598;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; DRUG SCREENING; FEEDING; KIDNEY FUNCTION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RAT; URINARY EXCRETION;

ANIMALS; BLOOD PRESSURE; BODY WEIGHT; DIABETIC NEPHROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIN-1; ENDOTHELINS; KIDNEY FUNCTION TESTS; MALE; PYRIMIDINES; RATS; RATS, INBRED OLETF; RECEPTOR, ENDOTHELIN A; RECEPTORS, ENDOTHELIN; SULFONAMIDES;

EID: 0037162699     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)02006-X     Document Type: Article

References (39)

1. Abassi Z.A., Klein H., Golomb E., Keiser H.R. Urinary endothelin: a possible bilogical marker of renal damage. Am. J. Hypertens. 6:1993;1046-1054.
2. Benigni A., Colosio V., Brena C., Bruzzi I., Bertani T., Remuzzi G. Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes. Diabetes. 47:1998;450-456.
3. Benigni A., Perico N., Remuzzi G. Endothelin antagonists and renal protection. J. Cardiovasc. Pharmacol. 35(Suppl. 2):2000;S75-S78.
4. Fukui M., Nakamura T., Ebihara I., Osada S., Tomino Y., Masaki T., Goto K., Furuichi Y., Koide H. Gene expression for endothelins and their receptors in glomeruli of diabetic rats. J. Lab. Clin. Med. 122:1993;149-156.
5. Fukuzawa Y., Watanabe Y., Inaguma D., Hotta N. Evaluation of glomerular lesion and abnormal urinary findings in OLETF rats resulting from a long-term diabetic state. J. Lab. Clin. Med. 128:1996;568-578.
6. Gambaro G., Cicerello E., Mastrosimone S., Lavagnini T., Baggio B. High urinary excretion of glycosaminoglycans: a possible marker of glomerular involvement in diabetes. Metabolism. 38:1989;419-420.
7. Harada H., Kazumi J., Watanuki S., Tsuzuki R., Sudoh K., Fujimori A., Tokunaga T., Tanaka A., Tsukamoto S., Yanagisawa I. Synthesis and structure-activity relationships in a series of ethenesulfonamide derivatives, a novel class of endothelin receptor antagonists. Chem. Pharm. Bull. 49:2001;1593-1603.
8. Hayashi Y., Makino H., Ota Z. Serum and urinary concentrations of type IV collagen and laminin as a marker of microangiopathy in diabetes. Diabet. Med. 9:1992;366-370.
9. Hocher B., Thöne-Reineke C., Bauer C., Raschack M., Neumayer H.H. The paracrine endothelin system: pathophysiology and implications in clinical medicine. Eur. J. Clin. Chem. Clin. Biochem. 35:1997;175-189.
10. Hocher B., Lun A., Priem F., Neumayer H.-M., Raschack M. Renal endothelin system in diabetes: comparison of angiotensin-converting enzyme inhibition and endothelin-A antagonism. J. Cardiovasc. Pharmacol. 31(Suppl. 1):1998;S492-S495.
11. Hopfner R.L., Gopalakrishnan V. Endothelin: emerging role in diabetic vascular complications. Diabetologia. 42:1999;1383-1394.
12. Iwasaki S., Homma T., Matsuda Y., Kon V. Endothelin receptor subtype B mediates auto-induction of endothelin-1 in rat mesangial cells. J. Biol. Chem. 270:1995;6997-7003.
13. Kado S., Aoki A., Wada S., Katayama Y., Kugai N., Yoshizawa N., Nagata N. Urinary type IV collagen as a marker for early diabetic nephropathy. Diabetes Res. Clin. Pract. 31:1996;103-108.
14. Kasiske B.L., Kalil R.S.N., Ma J.Z., Liao M., Keane W.F. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann. Intern. Med. 118:1993;129-138.
15. Kawano K., Hirashima T., Mori S., Saitoh Y., Kurosumi M., Natori T. Spontaneous long-term hyperglycemic rat with diabetic complications: Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes. 41:1992;1422-1428.
16. Keane W.F., Mulcahy W.S., Kasiske B.L., Kim Y., O'Donnell M.P. Hyperlipidemia and progressive renal disease. Kidney Int. 39(Suppl. 31):1991;S41-S48.
17. Kramer-Guth A., Quaschning T., Greiber S., Wanner C. Potential role of lipids in the progression of diabetic nephropathy. Clin. Nephrol. 46:1996;262-265.
18. Lee S.-Y., Shin S.-J., Tsai J.-H. Increased urinary endothelin-1 like immunoreactivity in NIDDM patients with albuminuria. Diabetes Care. 17:1994;263-266.
19. Lott J.A., Turner K. Evaluation of Trinder's glucose oxidase method for measuring glucose in serum and urine. Clin. Chem. 21:1975;1754-1760.
20. Moorhead J.F., Chan M.K., El-Nahas M., Varghese Z. Lipid nephrotoxicity in chronic progression glomerular and tubulo-interstitial disease. Lancet. ii:1982;1309-1311.
21. Ohkubo Y., Kishikawa H., Araki E., Miyata T., Isami S., Motoyoshi S., Kojima Y., Furuyoshi N., Shichiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res. Clin. Pract. 28:1995;103-117.
22. Ohta K., Hiarata Y., Shichiri M., Kanno K., Emori T., Tomita K., Marumo F. Urinary excretion of endothelin-1 in normal subjects and patients with renal disease. Kidney Int. 39:1991;307-311.
23. Ong A.C.M., Jowett T.P., Firth J.D., Burton S., Karet F.E., Fine E.G. An endothelin-1 mediated autocrine growth loop involved in human renal tubular regeneration. Kidney Int. 48:1995;390-401.
24. Parving H.-H., Andersen A.R., Hommel E., Smidt U. Effects of long-term antihypertensive treatment on kidney function in diabetic nephropathy. Hypertension. 7(Suppl. II):1985;II114-II117.
25. Parving H.-H., Anderson A.R., Smidt U., Hommel E., Mathiesen E.R., Svendsen P.A. Effects of antihypertensive treatment on kidney function in diabetic nephropathy. BMJ. 294:1987;1443-1447.
26. Parving H.-H., Hommel E., Smidt U.M. Protection of kidney function and decrease in albuminuria by captopril in insulin-dependent diabetes with nephropathy. BMJ. 297:1988;1086-1091.
27. Rohrbach D.H., Hassell J.R., Kleinman H.K., Martin G.R. Alterations in the basement membrane (heparan sulfate) proteoglycan in diabetic mice. Diabetes. 31:1982;185-188.
28. Ruíz-Ortega M., Gómez-Garre D., Alcázar R., Palacios I., Bustos C., González S., Plaza J.J., González E., Egido J. Involvement of angiotensin II and endothelin in matrix protein production and renal sclerosis. J. Hypertens. 12:1994;S51-S58. (Supplement).
29. Saijonmaa O., Nyman T., Fyhrquist F. Endothelin-1 stimulates its own synthesis in human endothelial cells. Biochem. Biophys. Res. Commun. 188:1992;286-291.
30. A receptor selective antagonist. Arch. Pharmacol. 358(Suppl. 2):1998;R397.
31. Shin S.-J., Lee Y.-J., Tsai J.-H. The correlation of plasma and urine endothelin-1 with the severity of nephropathy in Chinese patients with type 2 diabetes. Scand. J. Clin. Lab. Invest. 56:1996;571-576.
32. c-src. J. Biol. Chem. 268:1993;9347-9357.
33. Sugimoto K., Tsuruoka S., Fujimura A. Hyperlipidaemia and the progression of nephropathy in OLETF rats: effect of angiotensin-converting enzyme inhibitor, enalapril. Clin. Exp. Pharmacol. Ther. 26:1999;601-607.
34. The Microalbuminuria Captopril Study Group Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia. 39:1996;587-593.
35. Van den Lest C.H.A., Versteeg E.M.M., Veerkamp J.H., Van Kuppevelt T.H. A spectrophotomeric method for the determination of heparan sulfate. Biochim. Biophys. Acta. 1201:1994;305-314.
36. Vlachojannis J., Tsakas S., Petropoulou C., Kurz P. Increased renal excretion of endothelin-1 in nephrotic patients. Nephrol. Dial. Transplant. 12:1997;470-473.
37. A. J. Am. Soc. Nephrol. 5:1994;1074-1080.
38. Yamauchi T., Ohnaka K., Takayanagi R., Umeda F., Nawata H. Enhanced secretion of endothelin-1 by elevated glucose levels from cultured bovine aortic endothelial cells. FEBS Lett. 267:1990;16-18.
39. Zoja C., Morigi M., Figliuzzi M., Bruzzi I., Oldroyd S., Benigni A., Ronco P., Remuzzi G. Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins. Am. J. Kidney Dis. 26:1995;934-941.